---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-016343"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2024-12-18T23:59:59+00:00"
generated_at: "2026-05-29T02:00:21.807273+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Corvus reports positive interim Phase 1 soquelitinib data in atopic dermatitis; $12.7M warrant exercise

## Summary
- Soquelitinib 100mg BID: mean EASI reduction 55.9% at Day 28 vs 27% placebo; 69.1% at Day 58 vs 19.1% placebo.
- At Day 58, 90% of soquelitinib patients achieved EASI-50, 40% EASI-75, 10% EASI-90 vs 25%, 0%, 0% for placebo.
- No significant safety issues; only Grade 1 nausea (1 patient) and COVID-19 (1 patient) reported.
- Samlyn Capital exercised all warrants for 3,633,978 shares, generating ~$12.7M cash proceeds.
- Initial Cohort 2 data (200mg once daily) in 12 patients consistent with Cohort 1; no treatment-related AEs.

## SEC filing metadata
- accession: 0001558370-24-016343
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2024-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000155837024016343/0001558370-24-016343-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000155837024016343/crvs-20241218x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-016343
- JSON: https://secwatch.observer/filing/0001558370-24-016343.json
- Plain text: https://secwatch.observer/filing/0001558370-24-016343.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.